The firm has said that it intends to use the net proceeds and available cash to redeem its outstanding 5.25 percent senior notes due in 2022 in the amount of $1 billion.
Underwriter Merrill Lynch exercised in full the option to purchase up to an additional $90M in senior notes on top of a $600M notes offering announced last week.
The firm intends to use the net proceeds and available cash to redeem its outstanding 5.25 percent senior notes due 2022 in the amount of $1 billion.
With WHO prequalification, global health organizations can consider the Aptima HIV-1 Quant Dx for public-sector procurement in resource-limited countries.
The company said it will use the proceeds from the offering for general corporate and working capital purposes.
The firm intends to use the net proceeds of the offering and available cash to retire its remaining convertible notes when they become callable.
The firm said that it expects to use the proceeds of the senior notes offering to contribute to retirement of remaining convertible notes.
The firm said it intends to use net proceeds from the issuance of the notes for general corporate purposes.
The offering consists of two tranches of $600 million each, and the firm plans to use the net proceeds for general corporate purposes, including the repayment of outstanding senior notes due on Aug. 23.
The company is aiming to raise $1.5 billion through the issuance of 3.2% senior notes due 2027 and 4.1% senior notes due 2047.
A new study in JAMA finds that genetic tests might not be able to determine what diet is right for someone seeking to lose weight.
A genome-wide association study that linked common genetic variants to salivary gland carcinoma risk has been retracted, according to Retraction Watch.
Vampire bats' ability to live off blood is etched in their genomes and gut microbiomes, the Scientist reports.
In Genome Biology this week: peopling of the Sahara, epigenetic reprogramming analysis of liverwort, and more.